|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Elan Insanity, Walter's Wild Ride, Pratt's Spat and Oy Vey Orchard highlight Gregg Greenberg's list this week of the Street's dumbest items.
Stock futures remain in the green as the Fed begins its meeting and investors process a moderate inflation report.
Elan Corporation, plc (NYSE: ELN) (Elan or the Company) today advises Elan Shareholders to withdraw any acceptances of Royalty Pharma’s Offer without delay and not to tender any further acceptances.
Royalty Pharma is going to court to re-instate its hostile tender offer for Elan following a shareholder vote.
Elan Corporation, plc (NYSE:ELN) (Elan or the Company) announces that, at its Extraordinary General Meeting held earlier today, shareholders approved the Share Repurchase Program.
Major U.S. stock averages retreated Friday as the market remained skittish amid tepid economic reports.
The latest twist in the contentious battle for Elan as it fights a takeover by Royalty Pharma.
Elan Corporation, plc (NYSE:ELN) (Elan or the Company) today announced that it is proceeding with a formal sale process in light of the expressions of interest received to date.
Here's a look at how to trade some of the most active stocks on the market today.
Stock futures continue to point to a lower open after April's retail sales numbers rise.
A strong dollar pulls down oil and gold, as Bloomberg comes under fire for its privacy breach, while Elan and Theravance agree to a deal.
U.S. stock futures point lower ahead of a retail sales report; Elan and Theravance in a $1 billion royalty agreement; Post Holdings and Take-Two report earnings.
Elan and Theravance enter a $1 billion royalty agreement.
He believes the palifosfamide sarcoma study to be released next week will be a failure.
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results from several studies of TYSABRI ® (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS)...
Two units of SAC Capital Advisors will pay more than $614 million in what federal regulators are calling the largest insider trading settlement ever.
Elan Corporation, plc (NYSE:ELN) (the Company) today disclosed the Tender Offer documentation for the Share Repurchase has been filed and is available on the Company’s website at www.
Major U.S. stock averages move higher in late trading on Monday as the Dow ignores worries about the end of its rally.
Elan Corporation, plc (NYSE:ELN) (the Company) today provides an update on the Tysabri Restructuring Transaction (“the Tysabri Transaction”) announced on February 6, 2013 and further information regarding the ...
The Board of Elan Corporation, plc (NYSE:ELN) (the Company) acknowledges this morning's statement by Royalty Management, LLC (Royalty Pharma).
The Board of Elan Corporation, plc (NYSE:ELN) (the Company) has approved the decision to initiate a unique cash dividend policy enabling its shareholders to benefit directly from the long term cash flow generated by...
A U.S. pharmaceutical investor just made a $6.55 billion offer that should make markets sit up and take notice.
Elan Corporation, plc (NYSE:ELN) today announced the appointment of Mr.
The Board of Elan Corporation, plc (NYSE:ELN) (the Company) acknowledges this morning's announcement by Royalty Management, LLC (Royalty Pharma) regarding an indicative, conditional, proposal which may or may not lead ...
Royalty's $11-per-share takeover bid plays into shareholder fears that Elan will waste its cash windfall.
Elan Corporation, plc (NYSE:ELN) today provides an update to the market post the February 6, 2013 announcement regarding the restructuring of the Tysabri® collaboration with Biogen Idec.
Elan Corporation, plc (NYSE: ELN) today announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2012.
Here's a look at how to trade some of the most active names on the market today.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.